Progentos Therapeutics closes USD 65MLn in series A financing

Progentos Therapeutics Closes $65 Million Series A Financing to Advance Treatments for Multiple Sclerosis and Other Degenerative Diseases

Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, recently announced its launch and the closing of a $65 million series A round. This funding will enable Progentos to advance its MS program through human proof of concept […]